Recent studies by Matusiak et al. suggest that the targets of anti-CD47 and anti-PD-L1 immunotherapy in CRC are IL-4I1+ macrophages, which may affect the phagocytic potential of TAMs. This evidence concerns the gene IL4I1 and colorectal carcinoma.